Rewiring Speech in Autism: A Ketamine Infusion Hypothesis

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by persistent social communication deficits and repetitive behaviors, with communication abilities ranging from nonverbal to verbally fluent yet socially impaired. These deficits, linked to disrupted neural connectivity in regions like the posterior superior temporal sulcus (pSTS), reward circuits, and dorsal/ventral speech pathways, profoundly affect fluency and social interaction. Current interventions, such as behavioral therapies, often fail to address these underlying neurobiological disruptions, necessitating innovative approaches. This paper proposes a novel therapeutic hypothesis: subanesthetic ketamine infusions during adolescent neuronal pruning (ages 15-20) to enhance social communication in ASD. Ketamine, an NMDA receptor antagonist, induces synaptic plasticity via glutamate release, AMPA receptor activation, and BDNF-mTOR signaling, potentially restoring connectivity in impaired circuits critical for speech perception and production. Preclinical studies show ketamine mitigates social deficits in ASD models, while preliminary human data suggest short-term alleviation of social withdrawal and emotional symptoms. Targeting adolescence leverages heightened plasticity during synaptic pruning, a critical period for refining language and social networks, offering an optimal window to reshape connectivity deficits unique to ASD. Unlike its traditional use in mood disorders, this approach uniquely focuses on communication impairments, addressing a therapeutic gap. However, limited empirical evidence underscores the need for randomized controlled trials to validate efficacy, safety, and optimal protocols across ASD's heterogeneity. If substantiated, this hypothesis could transform ASD management, bridging neurobiology and clinical practice to improve quality of life.